Posts in tag
G12C
Guardant Health and Amgen to Develop CDx Test for AMG 510 in KRAS G12C+ NSCLC
To support the commercialization of the blood-based companion diagnostic (CDx) test Guardant360 CDx for AMG 510, Guardant Health, Inc, will collaborate with Amgen, developer of AMG 510, and pursue an FDA Pre-Market Approval as a CDx for AMG 510 in patients with metastatic non–small cell lung cancer (NSCLC) with a KRAS G12C mutation, according to a press …
